ArticleTheranostics2019

Targeting PRMT5 Activity Inhibits the Malignancy of Hepatocellular Carcinoma by Promoting the Transcription of HNF4α.

Bai-Nan Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.